Clinical MilestonesThe completion of enrollment for the Phase 3 ONWARD program is a significant milestone, allowing for topline results to be available.
Financial StabilityThe merger of Acelyrin and Alumis has closed, securing a financial runway for Alumis well beyond the anticipated Phase 3 readout.
Regulatory PathThe potential accelerated regulatory path for ESK-001 in psoriasis, with a filing of 24-week results and subsequent submission of 52-week data, indicates confidence in the product's approval process.